Skip to content
OpenCapital
Get started

Organon OGN Europe and Canada — Revenue

Other geography segments

Latin America, Middle East, Russia, and Africa
$247M+2.9%
Asia Pacific and Japan
$226M-10.0%
Other
$23M-23.3%

Similar metrics at other companies

Eli Lilly logo
LLYEurope — Revenue
$3.65B+52.6%
Gilead Sciences logo
GILDEurope — Total revenues
$1.14B+5.5%
Vertex Pharmaceuticals logo
VRTXEurope — Product revenues, net
$950M+14.9%
Unifirst logo
UNFEurope And Canada — Revenue
$46.61M-1.9%
Moderna logo
MRNAEurope — Total Revenue
$13.25M-91.1%
Rigetti Computing, Inc. logo
RGTIEurope — Revenue
$592K-41.6%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's europe and canada — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's europe and canada — revenue?
Organon (OGN) reported europe and canada — revenue of $412M in Q1 2026.
How has Organon's europe and canada — revenue changed year-over-year?
Organon's europe and canada — revenue increased by 9.6% year-over-year, from $376M to $412M.
What is the long-term trend for Organon's europe and canada — revenue?
Over 4 years (2021 to 2025), Organon's europe and canada — revenue has grown at a -1.8% compound annual growth rate (CAGR), from $1.74B to $1.62B.
What does europe and canada — revenue mean?
This metric represents the total gross sales generated from pharmaceutical products and health solutions within the Europe and Canada geographic segment. It serves as a key indicator of the company's market penetration and commercial performance in these specific developed markets. Tracking this revenue stream helps investors evaluate the stability and growth trajectory of the company's established brand and biosimilar portfolios in these regions.